<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>AMMONUL- sodium phenylacetate and sodium benzoate injection, solution, concentrate </strong><br>Valeant Pharmaceuticals North America LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use AMMONUL<span class="Sup">®</span> safely and effectively. See full prescribing information for AMMONUL<span class="Sup">®</span>.
      <br><br>AMMONUL<span class="Sup">®</span> (sodium phenylacetate and sodium benzoate) injection, for <br> intravenous use <br>Initial U.S. Approval: 1987</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">AMMONUL is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> and associated <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> in patients with deficiencies in enzymes of the urea cycle. (<a href="#S1">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>AMMONUL must be diluted with sterile 10% Dextrose Injection (D10W) before administration. Administration must be through a central venous catheter. Administration through a peripheral line may cause <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>. (<a href="#S2">2</a>)</li>
<li>AMMONUL is administered intravenously as a loading dose infusion administered over 90 to 120 minutes, followed by an equivalent maintenance dose infusion administered over 24 hours.  (<a href="#S2">2</a>)</li>
</ul></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Injection: 10% per 10%  sterile, concentrated, aqueous solution of sodium phenylacetate and sodium benzoate. (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None (<a href="#S4">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>
<span class="Underline">Management of Acute <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span></span>: Monitor plasma <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> levels during treatment. Prolonged exposure to elevated plasma <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> levels can rapidly result in injury to the brain or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Prompt use of all therapies necessary to reduce plasma <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> levels is essential. (<a href="#S5.1">5.1</a>) </li>
<li>
<span class="Underline">Decreased Potassium Levels</span>: Plasma potassium levels should be carefully monitored and appropriate treatment given when necessary. (<a href="#S5.2">5.2</a>) </li>
<li>
<span class="Underline">Conditions Associated with <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">Fluid Overload</span></span>: AMMONUL contains 30.5 mg of sodium per mL of undiluted product. Caution should be used if AMMONUL is administered to patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, or with conditions in which there is <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span> with <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. (<a href="#S5.3">5.3</a>)</li>
<li>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span></span>: <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> of AMMONUL into the perivenous tissues during high flow bolus infusion may lead to <span class="product-label-link" type="condition" conceptid="4317266" conceptname="Skin necrosis">skin necrosis</span>, especially in infants. The infusion site must be monitored closely for possible tissue infiltration during drug administration. (<a href="#S5.4">5.4</a>)</li>
<li>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">Neurotoxicity</span> of Phenylacetate:</span> Because of prolonged plasma levels achieved by phenylacetate in pharmacokinetic studies, repeat loading doses should not be administered.  Additionally, <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> related to phenylacetate has been reported in cancer patients. Monitor patients for symptoms of acute <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>. (<a href="#S5.5">5.5</a>)</li>
<li>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">Hyperventilation</span> and <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic Acidosis</span>:</span> AMMONUL may cause side effects typically associated with salicylate <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, such as <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span> and <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>.  Monitor patient blood chemistry profiles and perform frequent blood pH and pCO<span class="Sub">2</span> measurements. (<a href="#S5.6">5.6</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most frequently reported adverse reactions (incidence ≥6%) are <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, and <span class="product-label-link" type="condition" conceptid="438409" conceptname="Attention deficit hyperactivity disorder">mental impairment</span>. (<a href="#S6">6</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Valeant Pharmaceuticals North America LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch.</span></span> </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Some antibiotics such as penicillin may affect the overall disposition of the infused drug. (<a href="#S7">7</a>)</li>
<li>Probenecid may affect renal excretion of phenylacetylglutamine and hippurate. (<a href="#S7">7</a>)</li>
<li>Valproic acid given to patients with urea cycle disorders may exacerbate their condition and antagonize the efficacy of AMMONUL through inhibition of the synthesis of N-acetylglutamate, a co-factor for carbamyl phosphate synthetase. (<a href="#S7">7</a>)</li>
<li>Use of corticosteroids may cause the breakdown of body protein and potentially increase plasma <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> levels in patients with impaired ability to form urea. (<a href="#S7">7</a>)</li>
</ul></div>
</div>
<div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 10/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1	INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommended Dose</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Administration</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4	CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Management of Acute <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Decreased Potassium Levels</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Conditions Associated with <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">Fluid Overload</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">Neurotoxicity</span> of Phenylacetate</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">Hyperventilation</span> and <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic Acidosis</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">7	DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8	USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1	Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3	Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Gender</a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.8 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics </a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1	INDICATIONS AND USAGE</h1>
<p class="First">AMMONUL is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> and associated <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> lowering therapies should be considered [see<span class="Italics"><a href="#S5"> Warnings and Precautions (5)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommended Dose</h2>
<p class="First">AMMONUL must be diluted with sterile 10% Dextrose Injection  (D10W) before administration. The dilution and dosage of AMMONUL are determined by weight for neonates, infants and young children, and by body surface area for larger patients, including older children, adolescents, and adults (Table 1). </p>
<table width="100%">
<caption><span>Table 1: Dosage and Administration</span></caption>
<col align="center" valign="top" width="25%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="center">Patient Population</th>
<th class="Rrule" align="center" colspan="2">Components of Infusion Solution<br>AMMONUL must be diluted with sterile 10% Dextrose Injection at ≥25 mL/kg before administration.</th>
<th class="Rrule" align="center" colspan="3" valign="top">Dosage Provided</th>
</tr>
<tr class="Botrule">
<th class="Lrule Rrule" align="center"></th>
<th class="Rrule" align="center" colspan="2"></th>
<th class="Rrule" align="center" colspan="3"></th>
</tr>
<tr class="Botrule Last">
<th class="Lrule Rrule" align="center"></th>
<th class="Rrule" align="center">AMMONUL</th>
<th class="Rrule" align="center">Arginine HCl Injection, 10%</th>
<th class="Rrule" align="center">Sodium Phenylacetate</th>
<th class="Rrule" align="center">Sodium Benzoate</th>
<th class="Rrule" align="center">Arginine HCl</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="center" colspan="6"><span class="Bold"><span class="Underline">Patients 0 to 20 kg:</span></span></td></tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="6"><span class="Bold">CPS and OTC Deficiency</span></td></tr>
<tr>
<td class="Lrule" align="center"><span class="Bold">Dose</span></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center">Loading: over 90 to 120 minutes</td>
<td class="Lrule Rrule" align="center">2.5 mL/kg</td>
<td class="Rrule" align="center">2 mL/kg</td>
<td class="Rrule" align="center">250 mg/kg</td>
<td class="Rrule" align="center">250 mg/kg</td>
<td class="Rrule" align="center">200 mg/kg</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">Maintenance: over 24 hours</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="6"><span class="Bold">ASS and ASL Deficiency</span></td></tr>
<tr>
<td class="Lrule Rrule" align="center"><span class="Bold">Dose</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">Loading: over 90 to 120 minutes</td>
<td class="Rrule" align="center">2.5 mL/kg</td>
<td class="Rrule" align="center">6 mL/kg</td>
<td class="Rrule" align="center">250 mg/kg</td>
<td class="Rrule" align="center">250 mg/kg</td>
<td class="Rrule" align="center">600 mg/kg</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Maintenance: over 24 hours</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="6"><span class="Bold"><span class="Underline">Patients &gt; 20 kg:</span></span></td></tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="6"><span class="Bold">CPS and OTC Deficiency</span></td></tr>
<tr>
<td class="Lrule Rrule" align="center"><span class="Bold">Dose</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">Loading: over 90 to 120 minutes</td>
<td class="Rrule" align="center">55 mL/m<span class="Sup">2</span>
</td>
<td class="Rrule" align="center">2 mL/kg</td>
<td class="Rrule" align="center">5.5 g/m<span class="Sup">2</span>
</td>
<td class="Rrule" align="center">5.5 g/m<span class="Sup">2</span>
</td>
<td class="Rrule" align="center">200 mg/kg</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Maintenance: over 24 hours</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="6"><span class="Bold">ASS and ASL Deficiency</span></td></tr>
<tr>
<td class="Lrule Rrule" align="center"><span class="Bold">Dose</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">Loading: over 90 to 120 minutes</td>
<td class="Rrule" align="center">55 mL/m<span class="Sup">2</span>
</td>
<td class="Rrule" align="center">6 mL/kg</td>
<td class="Rrule" align="center">5.5 g/m<span class="Sup">2</span>
</td>
<td class="Rrule" align="center">5.5 g/m<span class="Sup">2</span>
</td>
<td class="Rrule" align="center">600 mg/kg</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">Maintenance: over 24 hours</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Administration</h2>
<p class="First">AMMONUL is a concentrated solution and must be diluted before intravenous administration via a central venous catheter.  Administration through a peripheral intravenous catheter may cause <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>. AMMONUL may not be administered by any other route.</p>
<p>AMMONUL should be administered as a loading dose infusion over 90 to 120 minutes, followed by the same dose repeated as a maintenance infusion administered over 24 hours. Because of prolonged plasma levels achieved by phenylacetate in pharmacokinetic studies, repeat loading doses of AMMONUL should not be administered. Maintenance infusions may be continued until elevated plasma <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> levels have been normalized or the patient can tolerate oral nutrition and medications. An antiemetic may be administered during AMMONUL infusion to aid control of infusion-associated <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Administration of analogous oral drugs, such as sodium phenylbutyrate, should be terminated prior to AMMONUL infusion.</p>
<p>AMMONUL infusion should be started as soon as the diagnosis of <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> is made. Treatment of <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> also requires caloric supplementation and restriction of dietary protein. Non-protein calories should be supplied principally as glucose (8–10 mg/kg/min) with an intravenous fat emulsion added. Attempts should be made to maintain a caloric intake of greater than 80 kcal/kg/day. During and after infusion of AMMONUL, ongoing monitoring of the following clinical laboratory values is crucial: plasma <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span>, glutamine, quantitative plasma amino acids, blood glucose, electrolytes, venous or arterial blood gases, AST and ALT. On-going monitoring of the following clinical responses is also crucial to assess patient response to treatment: neurological status, Glasgow <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">Coma</span> Scale, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, CT or MRI scan or fundoscopic evidence of <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">cerebral edema</span>, and/or of gray matter and white matter damage. Hemodialysis should be considered in patients with severe <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> or who are not responsive to AMMONUL administration [see <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1)</a></span>]. In the non-neonatal study patient population treated with AMMONUL, dialysis was required in 13% of hyperammonemic episodes. Standard hemodialysis was the most frequently used dialysis method. High levels of <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> can be reduced quickly when AMMONUL is used with hemodialysis, as the <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span>-scavenging of AMMONUL suppresses the production of <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> from catabolism of endogenous protein and hemodialysis eliminates the <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> and <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> conjugates.</p>
<p>AMMONUL solutions are physically and chemically stable for up to 24 hours at room temperature and room lighting conditions. No compatibility information is presently available for AMMONUL infusion solutions except for Arginine HCl Injection, 10%, which may be mixed in the same container as AMMONUL. Other infusion solutions and drug products should not be administered together with AMMONUL infusion solution. AMMONUL solutions may be prepared in glass and PVC containers. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.1"></a><p></p>
<p class="First"><span class="Bold">Arginine Administration</span></p>
<p>Intravenous arginine is an essential component of therapy for patients with carbamyl phosphate synthetase (CPS), ornithine transcarbamylase (OTC), argininosuccinate synthetase (ASS), or argininosuccinate lyase (ASL) deficiency. Because <span class="product-label-link" type="condition" conceptid="4108257" conceptname="Metabolic acidosis, NAG, acidifying salts">hyperchloremic acidosis</span> may develop after high-dose arginine hydrochloride administration, chloride and <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> levels should be monitored and appropriate amounts of <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> administered.</p>
<p>In hyperammonemic infants with suspected, but unconfirmed urea cycle disorders, intravenous arginine should be given (6 mL/kg of Arginine HCl Injection 10%, over 90 minutes followed by the same dose given as a maintenance infusion over 24 hours). If deficiencies of ASS or ASL are excluded as diagnostic possibilities, the intravenous dose of Arginine HCl should be reduced to 2 mL/kg/day Arginine HCl Injection 10%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.2"></a><p></p>
<p class="First"><span class="Bold">Converting To Oral Treatment</span></p>
<p>Once elevated <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> levels have been reduced to the normal range, oral therapy, such as sodium phenylbutyrate, dietary management and maintenance protein restrictions should be started or reinitiated.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">AMMONUL (sodium phenylacetate and sodium benzoate) Injection 10% per 10% is a sterile, concentrated, aqueous solution of sodium phenylacetate and sodium benzoate.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4	CONTRAINDICATIONS</h1>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Management of Acute <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span></h2>
<p class="First">Any episode of acute symptomatic <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> should be treated as a life-threatening emergency. Uncontrolled <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> can rapidly result in <span class="product-label-link" type="condition" conceptid="4080670" conceptname="Brain damage">brain damage</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, and prompt use of all therapies necessary, including hemodialysis, to reduce <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> levels is essential.</p>
<p>Hyperammonemic <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> (regardless of cause) in the newborn infant should be aggressively treated while the specific diagnosis is pursued. Hemodialysis should be promptly initiated in all newborn patients. A blood flow rate of 150 mL/min/m<span class="Sup">2</span> should be targeted (<span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> clearance [mL/min] is similar to the blood flow rate [mL/min] through the dialyzer).  Clearance of <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> is approximately ten times greater by hemodialysis than by peritoneal dialysis or hemofiltration. Exchange transfusion is ineffective in the management of <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span>.  Hemodialysis may be repeated until the plasma <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> level is stable at normal or near normal levels.</p>
<p><span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span> due to urea cycle disorders should be managed in coordination with medical personnel experienced in <span class="product-label-link" type="condition" conceptid="436670" conceptname="Metabolic disease">metabolic disorders</span>. Ongoing monitoring of plasma <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> levels, neurological status, laboratory tests, and clinical response in patients receiving AMMONUL is crucial to assess patient response to treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Decreased Potassium Levels</h2>
<p class="First">Because urine potassium loss is enhanced by the excretion of the non-reabsorbable anions, phenylacetylglutamine and hippurate, plasma potassium levels should be carefully monitored and appropriate treatment given when necessary. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Conditions Associated with <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">Fluid Overload</span></h2>
<p class="First">AMMONUL contains 30.5 mg of sodium per mL of undiluted product. Thus, AMMONUL should be used with great care, if at all, in patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> or severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, and in clinical states in which there is <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span> with <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. Discontinue administration of AMMONUL, evaluate the patient, and institute appropriate therapeutic countermeasures if an adverse event occurs. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span></h2>
<p class="First"><span class="Underline">Administration must be through a central line. Administration through a peripheral line may cause <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span></span>. Bolus infusion flow rates are relatively high, especially for infants [see <span class="Italics"><a href="#S2">Dosage and Administration (2)</a></span>]. <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> of AMMONUL into the perivenous tissues may lead to <span class="product-label-link" type="condition" conceptid="4317266" conceptname="Skin necrosis">skin necrosis</span>. If <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> is suspected, discontinue the infusion and resume at a different infusion site, if necessary. The infusion site must be monitored closely for possible infiltration during drug administration. Do not administer undiluted product.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">Neurotoxicity</span> of Phenylacetate</h2>
<p class="First">Because of prolonged plasma levels achieved by phenylacetate in pharmacokinetic studies, repeat loading doses of AMMONUL should not be administered. Additionally, <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> was reported in cancer patients receiving intravenous phenylacetate, 250–300 mg/kg/day for 14 days, repeated at 4-week intervals. Manifestations were predominantly <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, with less <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">frequent headaches</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hypoacusis</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, impaired memory, and exacerbation of a pre-existing <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>. The acute onset of symptoms upon initiation of treatment and reversibility of symptoms when the phenylacetate was discontinued suggest a drug effect [see <span class="Italics"><a href="#S13.2">Animal Toxicology and/or Pharmacology (13.2)</a>]</span>.
                        </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">Hyperventilation</span> and <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic Acidosis</span></h2>
<p class="First">Due to structural similarities between phenylacetate and benzoate to salicylate, AMMONUL may cause side effects typically associated with salicylate <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, such as <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span> and <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>. Monitoring of blood chemistry profiles, blood pH and pCO<span class="Sub">2</span> should be performed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>The safety data were obtained from 316 patients who received AMMONUL as emergency (rescue) or prospective treatment for <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> as part of an uncontrolled, open-label study. The study population included patients between the ages of 0 to 53 years with a mean (SD) of 6.2 (8.54) years; 51% were male and 49% were female who had the following diagnoses:  OTC (46%), ASS (22%), CPS (12%), ASL (2%), ARG (&lt;1%), THN (&lt;1%), and other (18%). </p>
<table width="70%">
<caption><span>Table 2: Adverse Reactions Occurring in ≥3% of Patients Treated with AMMONUL</span></caption>
<col align="left" valign="top" width="75%">
<col align="left" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">Patients<br>N=316</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Number of patients with any adverse event</td>
<td class="Rrule" align="center">163 (52%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Blood and lymphatic system disorders</td>
<td class="Rrule" align="center">35 (11%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td class="Rrule" align="center">12 (4%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">Disseminated intravascular coagulation</span></td>
<td class="Rrule" align="center">11 (3%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span></td>
<td class="Rrule" align="center">28 (9%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></td>
<td class="Rrule" align="center">42 (13%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">10 (3%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">9 (3%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">29 (9%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">General disorders and administration-site conditions</td>
<td class="Rrule" align="center">45 (14%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Injection-site reaction</td>
<td class="Rrule" align="center">11 (3%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td class="Rrule" align="center">17 (5%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></td>
<td class="Rrule" align="center">39 (12%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td class="Rrule" align="center">9 (3%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> and procedural complications</td>
<td class="Rrule" align="center">12 (4%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Investigations</td>
<td class="Rrule" align="left">32 (10%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Metabolism and nutrition disorders</td>
<td class="Rrule" align="center">67 (21%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">Acidosis</span></td>
<td class="Rrule" align="center">8 (3%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span></td>
<td class="Rrule" align="center">17 (5%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></td>
<td class="Rrule" align="center">22 (7%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></td>
<td class="Rrule" align="center">8 (3%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></td>
<td class="Rrule" align="center">23 (7%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic acidosis</span></td>
<td class="Rrule" align="center">13 (4%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></td>
<td class="Rrule" align="center">71 (22%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">Brain edema</span></td>
<td class="Rrule" align="center">17 (5%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">Coma</span></td>
<td class="Rrule" align="center">10 (3%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span></td>
<td class="Rrule" align="center">19 (6%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="438409" conceptname="Attention deficit hyperactivity disorder">Mental impairment</span></td>
<td class="Rrule" align="center">18 (6%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Psychiatric disorders</td>
<td class="Rrule" align="center">16 (5%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span></td>
<td class="Rrule" align="center">8 (3%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Renal and urinary disorders</td>
<td class="Rrule" align="center">14 (4%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></td>
<td class="Rrule" align="center">47 (15%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">Respiratory distress</span></td>
<td class="Rrule" align="center">9 (3%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Skin and subcutaneous tissue disorders</td>
<td class="Rrule" align="center">19 (6%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></td>
<td class="Rrule" align="center">19 (6%)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></td>
<td class="Rrule" align="center">14 (4%)</td>
</tr>
</tbody>
</table>
<p>Adverse reactions were reported with similar frequency in patients with OTC, ASS, CPS, and diagnoses categorized as "other." <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span> were more frequent in patients with OTC and CPS, compared with patients with ASS and patients with "other" diagnoses. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> and <span class="product-label-link" type="condition" conceptid="438409" conceptname="Attention deficit hyperactivity disorder">mental impairment</span> were reported in patients with OTC and CPS. These observations are consistent with literature reports that patients with enzyme deficiencies occurring earlier in the urea cycle (i.e., OTC and CPS) tend to be more severely affected.</p>
<p>Adverse reactions profiles differed by age group.  Patients ≤30 days of age had more blood and lymphatic system disorders and <span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">vascular disorders</span> (specifically <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>), while patients &gt;30 days of age had more <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span> (specifically <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>).</p>
<p>Less common adverse reactions (&lt;3% of patients) that are characterized as severe are listed below by body system.</p>
<p>BLOOD AND LYMPHATIC SYSTEM DISORDERS: <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulopathy</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span></p>
<p><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">CARDIAC DISORDERS</span>: <span class="product-label-link" type="condition" conceptid="4152594" conceptname="Atrial rupture">atrial rupture</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, cardiac or <span class="product-label-link" type="condition" conceptid="4256374" conceptname="Cardiorespiratory arrest">cardiopulmonary arrest</span>/failure, <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>, <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">pericardial effusion</span></p>
<p><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">EYE DISORDERS</span>: <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span></p>
<p><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">GASTROINTESTINAL DISORDERS</span>: <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdominal distension</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span></p>
<p>GENERAL DISORDERS AND ADMINISTRATION-SITE CONDITIONS:  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4048809" conceptname="Brainstem death">brain death</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4212484" conceptname="Multiple organ failure">multiorgan failure</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span></p>
<p>HEPATOBILIARY DISORDERS: <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>, <span class="product-label-link" type="condition" conceptid="4226129" conceptname="Hepatic artery stenosis">hepatic artery stenosis</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>/hepatotoxicity, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span></p>
<p><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span> AND <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">INFESTATIONS</span>: <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>/<span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span></p>
<p>INJURY, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">POISONING</span> AND PROCEDURAL COMPLICATIONS: <span class="product-label-link" type="condition" conceptid="4273850" conceptname="Brain stem herniation">brain herniation</span>, <span class="product-label-link" type="condition" conceptid="4318408" conceptname="Subdural hematoma">subdural hematoma</span>, <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span></p>
<p>INVESTIGATIONS: blood <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> changes, blood glucose changes, blood pH increased, <span class="product-label-link" type="condition" conceptid="4313695" conceptname="Decreased cardiac output">cardiac output decreased</span>, pCO<span class="Sub">2</span> changes, <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span> increased</p>
<p>METABOLISM AND NUTRITION DISORDERS: <span class="product-label-link" type="condition" conceptid="438730" conceptname="Alkalosis">alkalosis</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">fluid overload</span>/retention, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">hypernatremia</span>, <span class="product-label-link" type="condition" conceptid="438730" conceptname="Alkalosis">alkalosis</span>, <span class="product-label-link" type="condition" conceptid="380534" conceptname="Tetany">tetany</span></p>
<p>NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED:  <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangioma acquired</span></p>
<p><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">NERVOUS SYSTEM DISORDERS</span>: <span class="product-label-link" type="condition" conceptid="4290597" conceptname="Absent reflex">areflexia</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, brain <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>, brain <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4150603" conceptname="Cerebral atrophy">cerebral atrophy</span>, <span class="product-label-link" type="condition" conceptid="4270553" conceptname="Clonus">clonus</span>, <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">depressed level of consciousness</span>, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">nerve paralysis</span>, <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">intracranial pressure increased</span>, <span class="product-label-link" type="condition" conceptid="4318408" conceptname="Subdural hematoma">subdural hematoma</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span></p>
<p>PSYCHIATRIC DISORDERS: acute <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span></p>
<p>RENAL AND URINARY DISORDERS: <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span></p>
<p>RESPIRATORY, THORACIC AND <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">MEDIASTINAL DISORDERS</span>: <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">acute respiratory distress syndrome</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span>, <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span>, <span class="product-label-link" type="condition" conceptid="4190521" conceptname="Kussmaul's respiration">Kussmaul respiration</span>, <span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">pneumonia aspiration</span>, <span class="product-label-link" type="condition" conceptid="253796" conceptname="Pneumothorax">pneumothorax</span>, <span class="product-label-link" type="condition" conceptid="4301606" conceptname="Pulmonary hemorrhage">pulmonary hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="4048509" conceptname="Respiratory acidosis">respiratory acidosis</span> or <span class="product-label-link" type="condition" conceptid="438730" conceptname="Alkalosis">alkalosis</span>, <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>/failure</p>
<p>SKIN AND SUBCUTANEOUS TISSUE DISORDERS:  <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>, pruritis generalized, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></p>
<p><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">VASCULAR DISORDERS</span>: <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">phlebothrombosis</span>/<span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7	DRUG INTERACTIONS</h1>
<p class="First">Formal drug interaction studies have not been performed with AMMONUL.</p>
<p>Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug.</p>
<p>Probenecid is known to inhibit the renal transport of many organic compounds, including aminohippuric acid, and may affect renal excretion of phenylacetylglutamine and hippurate.</p>
<p>There have been reports that valproic acid can induce <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> through inhibition of the synthesis of N-acetylglutamate, a co-factor for carbamyl phosphate synthetase. Therefore, administration of valproic acid to patients with urea cycle disorders may exacerbate their condition and antagonize the efficacy of AMMONUL.</p>
<p>Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> levels in patients with impaired ability to form urea.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8	USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1	Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold">Pregnancy Category C.</span> Animal reproduction studies have not been conducted with AMMONUL. It is not known whether AMMONUL can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Thus, AMMONUL should be given to a pregnant woman only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3	Nursing Mothers</h2>
<p class="First">It is not known whether sodium phenylacetate, sodium benzoate, or their conjugation products are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when AMMONUL is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">AMMONUL has been used as a treatment for acute <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> in pediatric patients including patients in the early neonatal period [see <span class="Italics"><a href="#S2">Dosage and Administration (2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of AMMONUL did not include any patients aged 65 and over to determine whether they respond differently from younger patients. Urea cycle disorders are presently diseases of the pediatric and younger adult populations. No pharmacokinetic studies of AMMONUL have been performed in geriatric patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or other drug therapy in this patient population.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Gender</h2>
<p class="First">Pharmacokinetic parameters of AMMONUL were compared in healthy males and females. Bioavailability of both benzoate and phenylacetate was slightly higher in females than in males. However, conclusions cannot be drawn due to the limited number of subjects in this study.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></h2>
<p class="First">Limited information is available on the metabolism and excretion of sodium phenylacetate and sodium benzoate in patients with impaired hepatic function. However, metabolic conjugation of sodium phenylacetate and sodium benzoate is known to take place in the liver and kidney. Therefore, caution should be used in administering AMMONUL to patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.8"></a><a name="section-8.7"></a><p></p>
<h2>8.8 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The drug metabolites of AMMONUL (phenylacetylglutamine and hippurate) and subsequently <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> are primarily excreted by the kidney. Therefore, use caution and closely monitor patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> who receive AMMONUL.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Overdosage has been reported during AMMONUL treatment in urea cycle-deficient patients. All patients in the uncontrolled open-label study were to be treated with the same dose of AMMONUL. However, some patients received more than the dose level specified in the protocol.  In 16 of the 64 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>, the patient received a known <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of AMMONUL. Causes of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in these patients included cardiorespiratory failure/arrest (6 patients), <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> (3 patients), <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> (2 patients), <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> with <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span> and <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulopathy</span> (1 patient), error in dialysis procedure (1 patient), <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span> (1 patient), intractable <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and probable <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> (1 patient), and unknown (1 patient). Additionally, other signs of <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> may include <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">obtundation</span> (in the absence of <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span>), <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span>, a severe compensated <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, perhaps with a respiratory component, large <span class="product-label-link" type="condition" conceptid="4009397" conceptname="Anion gap">anion gap</span>, <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">hypernatremia</span> and hyperosmolarity, progressive <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>In case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of AMMONUL, discontinue the drug and institute appropriate emergency medical monitoring and procedures. In severe cases, the latter may include hemodialysis (procedure of choice) or peritoneal dialysis (when hemodialysis is unavailable).</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">AMMONUL (sodium phenylacetate and sodium benzoate) Injection 10% per 10% (a nitrogen binding agent), is a sterile, concentrated, aqueous solution of sodium phenylacetate and sodium benzoate. The pH of the solution is between 6 and 8. Sodium phenylacetate is a crystalline, white to off-white powder with a strong, offensive odor. It is soluble in water. Sodium benzoate is a white and odorless, crystalline powder that is readily soluble in water.</p>
<p><span class="Bold">Figure 1</span></p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e00521d3-84f1-4586-b4a8-9dc17ffffcb1&amp;name=ammonul-01.jpg"></p>
<p>Sodium phenylacetate has a molecular weight of 158.13 and the molecular formula C<span class="Sub">8</span>H<span class="Sub">7</span>NaO<span class="Sub">2</span>. Sodium benzoate has a molecular weight of 144.11 and the molecular formula C<span class="Sub">7</span>H<span class="Sub">5</span>NaO<span class="Sub">2</span>.</p>
<p>Each mL of AMMONUL contains 100 mg of sodium phenylacetate and 100 mg of sodium benzoate, and Water for Injection. Sodium hydroxide and/or hydrochloric acid may have been used for pH adjustment.</p>
<p>AMMONUL injection is a sterile, concentrated solution intended for intravenous administration via a central line only after dilution [see <span class="Italics"><a href="#S2">Dosage and Administration (2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Urea cycle disorders can result from <span class="product-label-link" type="condition" conceptid="4139968" conceptname="Underactive">decreased activity</span> of any of the following enzymes: <span class="Italics">N</span>-acetylglutamate synthetase (NAGS), carbamyl phosphate synthetase (CPS), argininosuccinate synthetase (ASS), ornithine transcarbamylase (OTC), argininosuccinate lyase (ASL), or arginase (ARG).</p>
<p>Sodium phenylacetate and sodium benzoate are metabolically active compounds that can serve as alternatives to urea for the excretion of waste nitrogen. Figure 2 is a schematic illustrating how the components of AMMONUL, phenylacetate and benzoate, provide an alternative pathway for nitrogen disposal in patients without a fully functioning urea cycle. Phenylacetate conjugates with glutamine in the liver and kidneys to form phenylacetylglutamine, via acetylation. Phenylacetylglutamine is excreted by the kidneys via glomerular filtration and tubular secretion. The nitrogen content of phenylacetylglutamine per mole is identical to that of urea (both contain two moles of nitrogen). Two moles of nitrogen are removed per mole of phenylacetate when it is conjugated with glutamine. Similarly, preceded by acylation, benzoate conjugates with glycine to form hippuric acid, which is rapidly excreted by the kidneys by glomerular filtration and tubular secretion. One mole of hippuric acid contains one mole of waste nitrogen. Thus, one mole of nitrogen is removed per mole of benzoate when it is conjugated with glycine. </p>
<p><span class="Bold">Figure 2</span></p>
<p><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e00521d3-84f1-4586-b4a8-9dc17ffffcb1&amp;name=ammonul-02.jpg"></p>
<p>CPS = carbamyl phosphate synthetase;<br>OTC = ornithine transcarbamylase;<br>ASS = argininosuccinate synthetase;<br>ASL = argininosuccinate lyase;<br>ARG = arginase;<br>NAGS = <span class="Italics">N</span>-acetylglutamate synthetase</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">In patients with <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> due to deficiencies in enzymes of the urea cycle, AMMONUL has been shown to decrease elevated plasma <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> levels. These effects are considered to be the result of reduction in nitrogen overload through glutamine and glycine scavenging by AMMONUL in combination with appropriate dietary and other supportive measures.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics </h2>
<p class="First">The pharmacokinetics of intravenously administered AMMONUL was characterized in healthy adult volunteers. Both benzoate and phenylacetate exhibited nonlinear kinetics. Following 90 minute intravenous infusion mean AUC<span class="Sub">last</span> for benzoate was 20.3, 114.9, 564.6, 562.8, and 1599.1 mcg/mL following doses of 1, 2, 3.75, 4, and 5.5 g/m<span class="Sup">2</span>, respectively. The total clearance decreased from 5.19 to 3.62 L/h/m<span class="Sup">2</span> at the 3.75 and 5.5 g/m<span class="Sup">2</span> doses, respectively.</p>
<p>Similarly, phenylacetate exhibited nonlinear kinetics following the priming dose regimens.  AUC<span class="Sub">last</span> was 175.6, 713.8, 2040.6, 2181.6, and 3829.2 mcg∙h/mL following doses of 1, 2, 3.75, 4, and 5.5 g/m<span class="Sup">2</span>, respectively.  The total clearance decreased from 1.82 to 0.89 mcg∙h/mL with increasing dose (3.75 and 4 g/m<span class="Sup">2</span>, respectively). </p>
<p>During the sequence of 90 minute priming infusion followed by a 24 hour maintenance infusion, phenylacetate was detected in the plasma at the end of infusion (T<span class="Sub">max</span> of 2 hr at 3.75 g/m<span class="Sup">2</span>) whereas, benzoate concentrations declined rapidly (T<span class="Sub">max</span> of 1.5 hr at 3.75 g/m<span class="Sup">2</span>) and were undetectable at 14 and 26 hours following the 3.75 and 4 g/m<span class="Sup">2</span> dose, respectively.</p>
<p>A difference in the metabolic rates for phenylacetate and benzoate was noted.  The formation of hippurate from benzoate occurred more rapidly than that of phenylacetylglutamine from phenylacetate, and the rate of elimination for hippurate appeared to be more rapid than that for phenylacetylglutamine.</p>
<p>Pharmacokinetic observations have also been reported from twelve episodes of <span class="product-label-link" type="condition" conceptid="4143108" conceptname="Hyperammonemic encephalopathy">hyperammonemic encephalopathy</span> in seven children diagnosed (age 3 to 26 months) with urea cycle disorders who had been administered AMMONUL intravenously. These data showed peak plasma levels of phenylacetate and benzoate at approximately the same times as were observed in healthy adults.  As in healthy adults, the plasma levels of phenylacetate were higher than benzoate and were present for a longer time.</p>
<p>The pharmacokinetics of intravenous phenylacetate have been reported following administration to adult patients with advanced <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span>. The decline in serum phenylacetate concentrations following a loading infusion of 150 mg/kg was consistent with saturable enzyme kinetics. Ninety-nine percent of administered phenylacetate was excreted as phenylacetylglutamine [2,3].</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies in animals have not been performed to evaluate the carcinogenic potential of AMMONUL. Studies to evaluate the possible impairment of fertility or mutagenic potential of AMMONUL have not been performed. Results indicate that sodium benzoate is not mutagenic or carcinogenic, and does not impair fertility.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="S13.2"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">In animal studies, subcutaneous administration to rat pups of 190–474 mg/kg of phenylacetate caused decreased proliferation and increased loss of neurons, and reduced central nervous system (CNS) myelin. Cerebral synapse maturation was retarded, and the number of functioning nerve terminals in the cerebrum was reduced, which resulted in impaired brain growth.  Pregnant rats were given phenylacetate at 3.5 µmol/g/day subcutaneously from gestation day 7 through normal delivery. Prenatal exposure of rat pups to phenylacetate produced lesions in layer 5 cortical pyramidal cells; dendritic spines were longer and thinner than normal and reduced in number.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The efficacy of AMMONUL in improving patient survival of acute hyperammonemic episodes was demonstrated in an analysis of 316 patients (1045 episodes of hospitalization) treated between 1981 and 2003. </p>
<p>The demographic characteristics and diagnoses of the patient population are shown in Table 3.</p>
<table width="75%">
<caption><span>Table 3: Baseline Characteristics and Diagnoses of Study Population</span></caption>
<col align="left" valign="top" width="33%">
<col align="left" valign="top" width="34%">
<col align="left" valign="top" width="33%">
<thead><tr class="First Last">
<th class="Lrule" align="left"></th>
<th class="Rrule" align="left"></th>
<th class="Rrule" align="left">Patients<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a><br>N=316</th>
</tr></thead>
<tfoot>
<tr class="First"><td align="left" colspan="3">OTC = ornithine transcarbamylase deficiency</td></tr>
<tr><td align="left" colspan="3">ASS = argininosuccinate synthetase deficiency</td></tr>
<tr><td align="left" colspan="3">CPS = carbamyl phosphate synthetase deficiency</td></tr>
<tr><td align="left" colspan="3">ASL = argininosuccinate lyase deficiency</td></tr>
<tr><td align="left" colspan="3">ARG = arginase deficiency</td></tr>
<tr class="Last"><td align="left" colspan="3">THN = transient <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> of the newborn</td></tr>
<tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>For the summary at the patient level, data obtained at first episode used.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Diagnosis unknown or pending (33 episodes), <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidemia</span> (14 episodes), HHH syndrome (6 episodes), carnitine translocase deficiency (4 episodes), liver disease (3 episodes), HMG CoA lyase deficiency (1 episode), non-ketotic hyperglycinemia (1 episode), suspected fatty acid oxidation deficiency (1 episode), and valproic-acid-induced <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> (1 episode).</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left">Gender</td>
<td class="Botrule Rrule Toprule" align="left">Male</td>
<td class="Botrule Rrule" align="center">158 (51%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="left">Female</td>
<td class="Rrule" align="center">150 (49%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Age (years)</td>
<td class="Botrule Rrule" align="left">N</td>
<td class="Botrule Rrule" align="center">310</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"></td>
<td class="Botrule Rrule" align="left">Mean (SD)</td>
<td class="Botrule Rrule" align="center">6.2 (8.54)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="left">Min–Max</td>
<td class="Rrule" align="center">0.0–53.0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Age groups</td>
<td class="Botrule Rrule" align="left">0–30 days</td>
<td class="Botrule Rrule" align="center">104 (34%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"></td>
<td class="Botrule Rrule" align="left">31 days–2 years</td>
<td class="Botrule Rrule" align="center">55 (18%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"></td>
<td class="Botrule Rrule" align="left">&gt;2–12 years</td>
<td class="Botrule Rrule" align="center">90 (29%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"></td>
<td class="Botrule Rrule" align="left">&gt;12–16 years</td>
<td class="Botrule Rrule" align="center">30 (10%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="left">&gt;16 years</td>
<td class="Rrule" align="center">31 (10%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Enzyme</td>
<td class="Botrule Rrule" align="left">OTC</td>
<td class="Botrule Rrule" align="center">146 (46%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">deficiency</td>
<td class="Botrule Rrule" align="left">ASS</td>
<td class="Botrule Rrule" align="center">71 (22%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"></td>
<td class="Botrule Rrule" align="left">CPS</td>
<td class="Botrule Rrule" align="center">38 (12%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"></td>
<td class="Botrule Rrule" align="left">ASL</td>
<td class="Botrule Rrule" align="center">7 (2%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"></td>
<td class="Botrule Rrule" align="left">ARG</td>
<td class="Botrule Rrule" align="center">2 (&lt;1%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"></td>
<td class="Botrule Rrule" align="left">THN</td>
<td class="Botrule Rrule" align="center">2 (&lt;1%)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="left">Other<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td class="Rrule" align="left">56 (18%)</td>
</tr>
</tbody>
</table>
<p>On admission to the hospital, patients with <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> and a suspected or confirmed urea cycle disorder (UCD) diagnosis were treated with a bolus dose of 0.25 g/kg (or 5.5 g/m<span class="Sup">2</span>) sodium phenylacetate + 0.25 g/kg (or 5.5 g/m<span class="Sup">2</span>) sodium benzoate over a period of 90 minutes to 6 hours, depending on the specific UCD. Infusions also contained arginine; the dose of arginine depended on the specific UCD. After completion of the bolus dose, maintenance infusions of the same dose over 24 hours were continued until the patient was no longer hyperammonemic or oral therapy could be tolerated. The mean (SD) duration of treatment was 4.6 (6.45) days per episode, and ranged from 1 to 72 days.</p>
<p>Survival was substantially improved after AMMONUL treatment compared with historical values (estimated 14% 1-year survival rate with dietary therapy alone) and with dialysis (estimated 43% survival of acute <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span>) . </p>
<p>Eighty percent of patients (252 of 316) survived their last episode. Of the 64 patients who died, 53 (83%) died during their first hyperammonemic episode. Of the 104 neonates (&lt;30d) treated with AMMONUL, 34 (33%) died during the first hyperammonemic episode.</p>
<p><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">Ammonia</span> levels decreased from very high levels (&gt;4 times the upper limit of normal [ULN]) to lower levels in 91% of episodes after treatment. In patients responding to therapy, mean <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> concentrations decreased from 200.9 µmol/L at hour zero to 101.6 µmol/L within four hours of initiation of AMMONUL therapy and were maintained. Hemodialysis is recommended for those patients whose plasma <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> levels fail to <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> below 150 µmol/L or by more than 40% within 4 to 8 hours after receiving AMMONUL. A shift from high (≤4 times ULN) to very high (&gt;4 times ULN) levels was observed in only 4% of the episodes.</p>
<p>Overall, investigators rated neurological status as improved, much improved, or the same in 93% of episodes, and overall status in response to treatment as improved, much improved, or the same in 97% of episodes. Recovery from <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> was observed in 97% of episodes where <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> was present at admission (111 of 114 episodes).</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">AMMONUL (sodium phenylacetate and sodium benzoate) Injection 10% per 10% is supplied in a single use glass vial. </p>
<p>NDC 0187-0010-50 single use vial containing 50 mL of sodium phenylacetate and sodium benzoate injection 10% per 10%.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First">Storage: Store at 25°C (77°F), excursions permitted to 15°–30°C (59°–86°F).</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Physicians should advise patients and caregivers about the following for safe use of AMMONUL:</p>
<ul>
<li> When plasma <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> levels have normalized, dietary protein intake can usually be increased with the goal of unrestricted protein intake.</li>
<li> Caution should be exercised when AMMONUL is administered to a nursing woman.</li>
<li> The most common adverse reactions are <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, and <span class="product-label-link" type="condition" conceptid="438409" conceptname="Attention deficit hyperactivity disorder">mental impairment</span>. </li>
<li> Generally BUPHENYL is stopped during the time AMMONUL is used.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<h1></h1>
<p class="First">Manufactured for:<br>Valeant Pharmaceuticals North America LLC<br>Bridgewater, NJ 08807 USA</p>
<p>By:<br>Cangene bioPharma, Inc.<br>Baltimore, MD 21230</p>
<p>Processed in the USA with Foreign Ingredients</p>
<p>9428200<br>Rev. 10/2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 50 mL Vial Carton</span></p>
<p><span class="Bold">NDC 0187-0010-50<br>Rx Only</span></p>
<p><span class="Bold">AMMONUL</span><span class="Sup">®</span><br>(sodium phenylacetate and<br>sodium benzoate) Injection</p>
<p><span class="Bold">10% / 10%</span></p>
<p><span class="Bold">50 mL<br>For IV use only</span></p>
<p><span class="Bold">Warning:</span> Administration must be through a central line.<br>Administration through a peripheral line may cause <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>.</p>
<p><span class="Bold">Must be diluted before IV administration</span></p>
<p>Sterile, non-pyrogenic, single use vial</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 50 mL Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e00521d3-84f1-4586-b4a8-9dc17ffffcb1&amp;name=ammonul-03.jpg"></div>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 50 mL Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e00521d3-84f1-4586-b4a8-9dc17ffffcb1&amp;name=ammonul-04.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMMONUL 		
					</strong><br><span class="contentTableReg">sodium phenylacetate and sodium benzoate injection, solution, concentrate</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0187-0010</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>sodium phenylacetate</strong> (phenylacetic acid) </td>
<td class="formItem">sodium phenylacetate</td>
<td class="formItem">100 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>sodium benzoate</strong> (benzoic acid) </td>
<td class="formItem">sodium benzoate</td>
<td class="formItem">100 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0187-0010-50</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">50 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020645</td>
<td class="formItem">02/17/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Valeant Pharmaceuticals North America LLC
							(042230623)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cangene bioPharma Inc</td>
<td class="formItem"></td>
<td class="formItem">050783398</td>
<td class="formItem">MANUFACTURE(0187-0010)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>5a561bf0-c3c8-41c2-85b9-e8614c030132</div>
<div>Set id: e00521d3-84f1-4586-b4a8-9dc17ffffcb1</div>
<div>Version: 1</div>
<div>Effective Time: 20141001</div>
</div>
</div> <div class="DistributorName">Valeant Pharmaceuticals North America LLC</div></p>
</body></html>
